Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease

Loading news article.

Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease | WAPE

Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease

Article summary

Related companies

Comments —